Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

RotaTeq

- PMLiVE

Merck’s Keytruda approved by EC for two new gastrointestinal cancer indications

Both approvals follow recommendations from the European Medicines Agency’s human medicines committee

- PMLiVE

GSK’s Jemperli combination receives EC approval for endometrial cancer

Up to 20% of endometrial cancer patients will have advanced disease at the time of diagnosis

- PMLiVE

GSK and GCOA report reveals global inequities in adult immunisation uptake

The report explored the social and structural factors of health in adult immunisation

- PMLiVE

UK Biobank reveals new data from world’s largest genetic project

The data will accelerate the development of potentially lifesaving treatments and cures

- PMLiVE

GSK global survey reveals misunderstandings about shingles in adults

About 55% of respondents believe that shingles can be caught from someone else

- PMLiVE

Merck shares positive phase 3 results for investigational pneumococcal vaccine in adults

V116 is designed to address the strains responsible for adult pneumococcal disease

- PMLiVE

GSK shares positive phase 3 results for Blenrep combination in multiple myeloma

Approximately 176,000 new cases of multiple myeloma are diagnosed globally each year

- PMLiVE

Merck’s Keytruda combination receives CHMP recommendation for biliary tract cancer

Approximately 211,000 people are diagnosed with the disease globally each year

- PMLiVE

GSK’s momelotinib recommended by CHMP to treat myelofibrosis patients with anaemia

About 40% of patients have moderate-to-severe anaemia at the time of diagnosis

- PMLiVE

Merck shares positive results for adjuvant Keytruda in phase 3 kidney cancer trial

Renal cell carcinoma accounts for approximately 90% of all kidney cancer diagnoses

- PMLiVE

Merck’s Keytruda combination granted FDA approval for biliary tract cancer

Approximately 20,000 people are diagnosed with the disease each year in the US

- PMLiVE

GSK to acquire exclusive rights to Janssen’s hepatitis B therapy in $1bn deal

GSK will evaluate the therapy in combination with its own hepatitis B treatment

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links